Lanrun Assets intends to become the largest shareholder of Yunsheng Medical by transferring the majority shareholder, but the original major shareholder Jiuchuan Group was involved in the debt litigation and the proposed transfer of shares was subject to judicial freezing, which cast a shadow over the transfer.
On the evening of July 5, Lanrun Assets and Yunsheng Medical announced that in order to smoothly transfer the shares, Lanrun Assets does not rule out the possibility of helping Jiuchuan Group to resolve related debt problems by providing assistance in negotiations, bridge funds and short-term loans. Sexuality, specific methods and methods still need to be further negotiated.
The proposed transfer of shares is frozen in full
On June 29, Yunsheng Medical announced that the major shareholder Shanghai Jiuchuan Investment (Group) Co., Ltd. intends to transfer its 53.5 million shares of the company to Lanrun Assets at a price of 15.7 yuan, with a total consideration of 840 million yuan. After the successful transfer of shares, Lanrun Assets will become the largest shareholder of the listed company.
It is understood that the stock price of Yunsheng Medical before the suspension is 13.77 yuan, Jiuchuan Group's transfer price is only a premium of 14%. The low transfer price has attracted the attention of the media and the Shanghai Stock Exchange.
On July 2, Yunsheng Medical disclosed that Jiuchuan Group was involved in a private lending dispute case. After the creditors applied to the court for compulsory execution, the 53.5 million shares of Yunsheng Medical held by Jiuchuan Group were all subject to judicial freezing. The freezing period was Three years. As of June 30, 2016, Jiuchuan Group has not paid the creditor's loan principal of RMB 10 million and the corresponding interest.
The proposed transfer of shares was subject to judicial freeze, and the plan for Lanrun Assets to obtain control of Yunsheng Medical has been difficult. Yunsheng Medical said in the evening announcement on July 5 that due to the complicated litigation of debts and debts of Jiuchuan Group, in order to smoothly transfer the shares, Lanrun Assets does not rule out the provision of assistance in negotiations, bridge funds and short-term loans. The possibility of Jiuchuan Group to resolve related debt problems.
The announcement also shows that the status of the restrictions on the rights of Yunsheng Medical Holdings held by Jiuchuan Group and its risks are also one of the basis for the lower transfer price.
In fact, it is not the first time that Jiuchuan Group’s equity in Yunsheng Medical has been frozen by the government. According to the Yunsheng Medical Announcement, from December 2014 to February this year, Jiuchuan Group’s shareholding in Yunsheng Medical has been frozen for six times due to private lending and contract disputes.
No clearly injected medical assets
In addition, although Lanrun Assets mentioned in the Equity Change Report that it will “inject medical-related quality assets†into Yunsheng Medical, the companies controlled by Lanrun Assets’ controlling shareholders and actual controllers and the main business are not related to medical care. Assets cause investors to have questions.
Yunsheng Medical replied that Lanrun Assets supports Yunsheng Medical to continue to focus on the medical service industry as a key business development in the future. It has already been in the field of medical rehabilitation and medical informationization , such as medical rehabilitation and medical information . The company has made early contact and negotiation, and has established a medical related professional team, but as of now, no suitable quality medical assets have been found.
However, Lanrun Assets also stated that the development plan of the above-mentioned medical service industry does not represent the commitment of Lanrun Assets and its related parties to listed companies and investors.
Cosmetics are a mixture of various raw materials processed by reasonable allocation. There are many kinds of cosmetics with different properties. According to the cosmetic raw material performance and use, can be divided into two categories of substrate raw materials and auxiliary raw materials. The former is a kind of main raw material of cosmetics, which occupies a large proportion in cosmetics formula and plays a major role in cosmetics. The latter play a role in shaping, stabilizing, or imbuing cosmetics with color, fragrance and other properties that are extremely important in small amounts in cosmetic formulations. Cosmetics is with natural, synthetic or extract all sorts of action different material as raw material, via heating, agitation and emulsification wait for production program processing and become chemical mixture material.
tryptamine labs review,tryptamine supplement,tryptamine high
Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptide-nootropic.com